NXGL Acquires Celularity Degenerative Disease Segment for $5.5M, Triples Revenue to $35M, Launches BioNX Surgical, Immediate Accretion, 6 Reimbursed Products, 3 510(k)s Planned 2026-2028
NexGel, Inc Common Stock · Now $0.59
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS